UPC
Universe Pharmaceuticals Inc.
There isn't enough reported data to score UPC yet.
UPC Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Strong |
UPC's balance sheet is currently strong, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.
UPC PE Valuation
UPC has no meaningful PE right now: it lost money over the past year.
UPC Forward outlook
There aren't enough analyst estimates for UPC to show an outlook.
UPC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2024 | -$3,054.00 | -$1,206.00 |
| Q3 2023 | -$1,020.00 | +$420.00 |
| Q3 2022 | -$1,440.00 | -167% |
UPC has swung to a loss: it lost $3,054.00 per share over the past year, after a profit the year before.
UPC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2024 | $23M | +66% |
| Q1 2024 | $12.9M | -30% |
| Q3 2023 | $13.8M | -13% |
| Q1 2023 | $18.5M | -24% |
| Q3 2022 | $15.9M | -67% |
| Q3 2021 | $48M | +213% |
| Q3 2020 | $15.4M | -7.6% |
| Q1 2020 | $15.4M | +85% |
UPC's revenue is recovering but still below its 2021 peak: $23M last quarter, up 44% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2024 | -35% | +36 points |
| Q1 2024 | -14% | -25 points |
| Q3 2023 | -27% | -55 points |
| Q1 2023 | 0.8% | -33 points |
| Q3 2022 | -71% | -105 points |
| Q1 2022 | 11% | -18 points |
| Q3 2021 | 28% | -1 points |
| Q3 2020 | 34% | -0.2 points |
UPC's operating margin was −35% last quarter, up 36 points from the same quarter a year ago, near the bottom of its range since 2018.
UPC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2024 | -$9.7M | -$6M |
| Q1 2024 | -$2.5M | -151% |
| Q3 2023 | -$3.7M | +$3.7M |
| Q1 2023 | $4.8M | -21% |
| Q3 2022 | -$7.5M | -$5M |
| Q3 2021 | -$2.5M | -182% |
| Q3 2020 | $3M | -54% |
| Q1 2020 | $3M | -7.6% |
UPC's free cash flow was −$11M over the past year, against −$874,723 the year before.
UPC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +35 shares |
| 1 year | +0.6% | +35 shares |
UPC has 6,077 diluted shares, up 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2020 | — |
| Q1 2020 | — |
| Q3 2019 | — |
| Q1 2019 | — |
| Q3 2018 | — |
| Q1 2018 | — |
UPC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2021 | -0.3x | Net Cash |
UPC has more cash than debt.
UPC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.5 | Neutral |
| Stochastic | 1.6 | Oversold |
UPC's weekly RSI is 36 (neutral) and its Stochastic is 2 (oversold).
UPC PE vs Healthcare Sector
| Metric | UPC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
UPC has no meaningful PE right now: it lost money over the past year.
UPC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.26 | 53% below |
| 20 week MA | $4.17 | 63% below |
| 50 week MA | $3.71 | 59% below |
| 100 week MA | $5.34 | 71% below |
| 200 week MA | $665.0 | 100% below |
UPC is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
UPC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $14,616.0 | $5,940.0 | -59% |
| 2022 | $5,940.0 | $5,796.0 | -2.4% |
| 2023 | $5,796.0 | $1,206.0 | -79% |
| 2024 | $1,206.0 | $24.9 | -98% |
| 2025 | $24.9 | $5.62 | -77% |
| 2026 YTD | $5.62 | $1.53 | -73% |
UPC has finished every year since 2021 lower, and it's down 73% so far in 2026.